Ascendiant Capital initiated coverage on Lucid Diagnostics with a new price target
$LUCD
Medical/Dental Instruments
Health Care
Ascendiant Capital initiated coverage of Lucid Diagnostics with a rating of Buy and set a new price target of $16.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/27/2021 | $16.00 | Buy | Ascendiant Capital |
| 12/15/2021 | $17.00 → $13.00 | Buy | Needham |
| 11/8/2021 | $18.00 | Buy | Canaccord Genuity |
| 11/8/2021 | $14.00 | Buy | BTIG Research |
| 11/8/2021 | $21.00 | Overweight | Cantor Fitzgerald |
| 11/8/2021 | $17.00 | Buy | Needham |
8-K - Lucid Diagnostics Inc. (0001799011) (Filer)
424B3 - Lucid Diagnostics Inc. (0001799011) (Filer)
EFFECT - Lucid Diagnostics Inc. (0001799011) (Filer)